Objective: The aim of the present study was to evaluate the antihypertensive efficacy of the
highly beta 1-selective adrenergic antagonist nebivolol in comparison with bisoprolol in the …

The objective of this 12‐week double‐blind randomized multicentre study was to compare
the efficacy and tolerability of nebivolol, a recently developed beta‐blocking agent with …

This double‐blind, multicenter, randomized placebo‐controlled study evaluated the
antihypertensive efficacy and safety of nebivolol, a selective β1‐adrenoreceptor blocker with …

Background and objective Lowering BP to normal levels without quality of life deterioration
is the most important means of reducing cardiovascular risk. Recent studies have …

Hypertension is a major cardiovascular risk factor but most patients remain asymptomatic for
many years. Successful therapy not only needs to be effective, it also needs to be well …

The β-adrenergic receptor blockers play an important role in the management of
cardiovascular disease, including hypertension and chronic heart failure. However …

Background: Nebivolol is a third-generation β1-selective β-blocker that is approved for the
treatment of hypertension. Objective: This article reviews the clinical pharmacology of …

Nebivolol is a lipophilic β 1-blocker. It is devoid of intrinsic sympathomimetic or membrane
stabilising activity but appears to have nitric oxide-mediated vasodilatory effects. Nebivolol is …

Objective: To assess the comparative tolerability of nebivolol and other cardioselective β-
blockers (CSBs) in the treatment of mild-to-moderate hypertension. Data source: Database …

Nebivolol, compared with classical β-blockers, exerts a high selectivity for β-adrenergic
receptors and also reduces peripheral vascular resistance by modulating nitric oxide (NO) …